Typical Dosing and Administration Protocols

Based on available clinical trial evidence, tesofensine dosing protocols have varied depending on the study population and indication:

Obesity Studies:

Doses ranging from 0.25 mg to 1.0 mg daily have been investigated in clinical trials
Some studies have evaluated tesofensine in combination with metoprolol (a beta-blocker) to potentially mitigate cardiovascular effects
Treatment durations in completed studies have ranged from single-dose pharmacokinetic studies to 48-week treatment periods

Parkinson's Disease Studies:

Earlier clinical development included investigation in Parkinson's disease patients, though specific dosing details from these studies are not detailed in the available evidence

Administration Considerations:

Clinical trials have examined both single-agent tesofensine and combination formulations with metoprolol
Studies have specifically monitored cardiovascular parameters including 24-hour heart rate monitoring, suggesting cardiovascular monitoring may be an important component of clinical protocols

Study Populations:

Clinical trials have enrolled patients with obesity, hypothalamic injury-induced obesity, type 2 diabetes mellitus, and Parkinson's disease
Treatment periods have extended up to 48 weeks in some safety and tolerability studies

Important Limitations:
The available evidence provides limited detail on specific dosing regimens, titration schedules, or administration timing. Most studies appear to be in Phase 1 or Phase 2 development stages.

Disclaimer: This information is derived from clinical research studies and is not personalized medical advice. Tesofensine is an investigational compound, and any clinical use should only occur under proper medical supervision within appropriate clinical trial settings or regulatory frameworks. Consult qualified healthcare professionals for medical guidance.

Tesofensine

Member access required